Literature DB >> 34044101

Systems biology evaluation of refractory Clostridioides difficile infection including multiple failures of fecal microbiota transplantation.

Anne J Gonzales-Luna1, Jennifer K Spinler2, Numan Oezguen2, Md Abdul Wadud Khan3, Heather A Danhof2, Bradley T Endres1, M Jahangir Alam1, Khurshida Begum1, Chris Lancaster1, Gabriela Pd Costa1, Tor C Savidge2, Julian G Hurdle4, Robert Britton2, Kevin W Garey5.   

Abstract

BACKGROUND: Fecal microbiota transplantation (FMT) aims to cure Clostridioides difficile infection (CDI) through reestablishing a healthy microbiome and restoring colonization resistance. Although often effective after one infusion, patients with continued microbiome disruptions may require multiple FMTs. In this N-of-1 study, we use a systems biology approach to evaluate CDI in a patient receiving chronic suppressive antibiotics with four failed FMTs over two years.
METHODS: Seven stool samples were obtained between 2016-18 while the patient underwent five FMTs. Stool samples were cultured for C. difficile and underwent microbial characterization and functional gene analysis using shotgun metagenomics. C. difficile isolates were characterized through ribotyping, whole genome sequencing, metabolic pathway analysis, and minimum inhibitory concentration (MIC) determinations.
RESULTS: Growing ten strains from each sample, the index and first four recurrent cultures were single strain ribotype F078-126, the fifth was a mixed culture of ribotypes F002 and F054, and the final culture was ribotype F002. One single nucleotide polymorphism (SNP) variant was identified in the RNA polymerase (RNAP) β-subunit RpoB in the final isolated F078-126 strain when compared to previous F078-126 isolates. This SNV was associated with metabolic shifts but phenotypic differences in fidaxomicin MIC were not observed. Microbiome differences were observed over time during vancomycin therapy and after failed FMTs.
CONCLUSION: This study highlights the importance of antimicrobial stewardship in patients receiving FMT. Continued antibiotics play a destructive role on a transplanted microbiome and applies selection pressure for resistance to the few antibiotics available to treat CDI. Crown
Copyright © 2021. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clostridium difficile; Metabolic analysis; Microbiome; N-of-1 studies; Shotgun sequencing

Mesh:

Substances:

Year:  2021        PMID: 34044101      PMCID: PMC8384661          DOI: 10.1016/j.anaerobe.2021.102387

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   2.837


  39 in total

1.  Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation.

Authors:  Jonathan U Peled; Antonio L C Gomes; Sean M Devlin; Eric R Littmann; Ying Taur; Anthony D Sung; Daniela Weber; Daigo Hashimoto; Ann E Slingerland; John B Slingerland; Molly Maloy; Annelie G Clurman; Christoph K Stein-Thoeringer; Kate A Markey; Melissa D Docampo; Marina Burgos da Silva; Niloufer Khan; André Gessner; Julia A Messina; Kristi Romero; Meagan V Lew; Amy Bush; Lauren Bohannon; Daniel G Brereton; Emily Fontana; Luigi A Amoretti; Roberta J Wright; Gabriel K Armijo; Yusuke Shono; Míriam Sanchez-Escamilla; Nerea Castillo Flores; Ana Alarcon Tomas; Richard J Lin; Lucrecia Yáñez San Segundo; Gunjan L Shah; Christina Cho; Michael Scordo; Ioannis Politikos; Kasumi Hayasaka; Yuta Hasegawa; Boglarka Gyurkocza; Doris M Ponce; Juliet N Barker; Miguel-Angel Perales; Sergio A Giralt; Robert R Jenq; Takanori Teshima; Nelson J Chao; Ernst Holler; Joao B Xavier; Eric G Pamer; Marcel R M van den Brink
Journal:  N Engl J Med       Date:  2020-02-27       Impact factor: 91.245

2.  Early Antibiotic Use After Fecal Microbiota Transplantation Increases Risk of Treatment Failure.

Authors:  Jessica R Allegretti; Dina Kao; Jessica Sitko; Monika Fischer; Zain Kassam
Journal:  Clin Infect Dis       Date:  2018-01-06       Impact factor: 9.079

3.  Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation.

Authors:  Ying Taur; Joao B Xavier; Lauren Lipuma; Carles Ubeda; Jenna Goldberg; Asia Gobourne; Yeon Joo Lee; Krista A Dubin; Nicholas D Socci; Agnes Viale; Miguel-Angel Perales; Robert R Jenq; Marcel R M van den Brink; Eric G Pamer
Journal:  Clin Infect Dis       Date:  2012-06-20       Impact factor: 9.079

4.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

Authors:  L Clifford McDonald; Dale N Gerding; Stuart Johnson; Johan S Bakken; Karen C Carroll; Susan E Coffin; Erik R Dubberke; Kevin W Garey; Carolyn V Gould; Ciaran Kelly; Vivian Loo; Julia Shaklee Sammons; Thomas J Sandora; Mark H Wilcox
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 9.079

5.  Bacterial colonization on writing pens touched by healthcare professionals and hospitalized patients with and without cleaning the pen with alcohol-based hand sanitizing agent.

Authors:  K Halton; V Arora; V Singh; S S Ghantoji; D N Shah; K W Garey
Journal:  Clin Microbiol Infect       Date:  2011-04-05       Impact factor: 8.067

6.  Increasing antibiotic resistance in Clostridioides difficile: A systematic review and meta-analysis.

Authors:  Srishti Saha; Saloni Kapoor; Raseen Tariq; Audrey N Schuetz; Pritish K Tosh; Darrell S Pardi; Sahil Khanna
Journal:  Anaerobe       Date:  2019-07-19       Impact factor: 3.331

7.  Duodenal infusion of donor feces for recurrent Clostridium difficile.

Authors:  Els van Nood; Anne Vrieze; Max Nieuwdorp; Susana Fuentes; Erwin G Zoetendal; Willem M de Vos; Caroline E Visser; Ed J Kuijper; Joep F W M Bartelsman; Jan G P Tijssen; Peter Speelman; Marcel G W Dijkgraaf; Josbert J Keller
Journal:  N Engl J Med       Date:  2013-01-16       Impact factor: 91.245

8.  Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.

Authors:  Derrick W Crook; A Sarah Walker; Yin Kean; Karl Weiss; Oliver A Cornely; Mark A Miller; Roberto Esposito; Thomas J Louie; Nicole E Stoesser; Bernadette C Young; Brian J Angus; Sherwood L Gorbach; Timothy E A Peto
Journal:  Clin Infect Dis       Date:  2012-08       Impact factor: 9.079

9.  Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection.

Authors:  Eugénie Bassères; Bradley T Endres; Mohammed Khaleduzzaman; Faranak Miraftabi; M Jahangir Alam; Richard J Vickers; Kevin W Garey
Journal:  J Antimicrob Chemother       Date:  2016-02-18       Impact factor: 5.790

10.  Dietary trehalose enhances virulence of epidemic Clostridium difficile.

Authors:  J Collins; C Robinson; H Danhof; C W Knetsch; H C van Leeuwen; T D Lawley; J M Auchtung; R A Britton
Journal:  Nature       Date:  2018-01-03       Impact factor: 49.962

View more
  5 in total

Review 1.  Computational approaches to understanding Clostridioides difficile metabolism and virulence.

Authors:  Matthew L Jenior; Jason A Papin
Journal:  Curr Opin Microbiol       Date:  2021-11-25       Impact factor: 7.934

2.  A Vancomycin HPLC Assay for Use in Gut Microbiome Research.

Authors:  Chenlin Hu; Nicholas D Beyda; Kevin W Garey
Journal:  Microbiol Spectr       Date:  2022-05-10

Review 3.  Genetic Mechanisms of Vancomycin Resistance in Clostridioides difficile: A Systematic Review.

Authors:  Taryn A Eubank; Anne J Gonzales-Luna; Julian G Hurdle; Kevin W Garey
Journal:  Antibiotics (Basel)       Date:  2022-02-16

4.  Functional and Metagenomic Evaluation of Ibezapolstat for Early Evaluation of Anti-Recurrence Effects in Clostridioides difficile Infection.

Authors:  Jacob McPherson; Chenlin Hu; Khurshida Begum; Weiqun Wang; Chris Lancaster; Anne J Gonzales-Luna; Caroline Loveall; Michael H Silverman; M Jahangir Alam; Kevin W Garey
Journal:  Antimicrob Agents Chemother       Date:  2022-07-06       Impact factor: 5.938

5.  Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial.

Authors:  Kevin W Garey; Jacob McPherson; An Q Dinh; Chenlin Hu; Jinhee Jo; Weiqun Wang; Chris K Lancaster; Anne J Gonzales-Luna; Caroline Loveall; Khurshida Begum; M Jahangir Alam; Michael H Silverman; Blake M Hanson
Journal:  Clin Infect Dis       Date:  2022-09-30       Impact factor: 20.999

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.